All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Andrew M. Brunner, Massachusetts General Hospital, Boston, US. We asked, Why is TIM-3 a good target for treating patients with high-risk MDS?
Why is TIM3 a good target for treating patients with high-risk MDS?
Current treatments available for patients with high-risk MDS achieve low overall response rates. In this video, Brunner explains the rationale for targeting TIM-3 in acute myeloid leukemia/MDS.
Practice-changing abstracts in myelodysplastic syndromes
World-leading experts in MDS shared the top abstracts from ASH 2020 that they believed could have the greatest impact on clinical practice.
Results from the phase II P-2001 study on pevonedistat plus azacytidine for high-risk MDS
To further explore the clinical efficacy and safety of pevo in patients with high-risk MDS, CMML, or low-blast AML, Mikkael Sekeres and colleagues designed the...
Subscribe to get the best content related to MDS delivered to your inbox